Rx License-Rx

TAB-2741

Fluorescent Primer(s) Creation for Nucleic Acid Detection and Amplification

CDC researchers have developed technology that consists of a simple and inexpensive technique for creating fluorescent labeled primers for nucleic acid amplification. Fluorescent chemical-labeled probes and primers are extensively used in clinical and research laboratories for rapid, real-time detection and identification of microbes and genetic sequences. During nucleic acid amplification, the "UniFluor" primer is incorporated into newly synthesized double stranded DNA. As a consequence, quenching of the dye's fluorescent signal occurs decreasing the fluorescence of the sample several fold. The decrease in fluorescence can be measured and observed using any commercially available nucleic acid amplification system that measures fluorescence (e.g., real-time PCR/thermocyclers). Because many real-time PCR applications require a multitude of fluorescently labeled primers or probes, the single-labeled primer technique also allows...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Neurology

Indication: Psychiatry/Mental Health

Modality: Biologic

Focus tags: Neurology, Ophthalmology, Oncology, Infectious Disease, Immunology, Cardiometabolic, Inflammation

Technology tags: Biologic, Diagnostic / Biomarker, AI / ML

Mechanism:

Development stage: Preclinical

Patent status: Abandoned; Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Neurology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Psychiatry/Mental Health. Public description: CDC researchers have developed technology that consists of a simple and inexpensive technique for creating fluorescent labeled primers for nucleic acid amplification. Fluorescent chemical-labeled probes and primers are extensively used in.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

The eye can create faster proof: Local delivery, imaging endpoints, and smaller patient groups can make ophthalmology assets easier to de-risk than broad systemic programs.

High upside if the mechanism is measurable: Neurology is hard, but biomarkers, retinal surrogates, genetics, or target-engagement readouts can turn a vague CNS story into a fundable experiment.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

CNS translation is unforgiving: Brain exposure, target engagement, endpoint sensitivity, and placebo/noise risk can make development expensive without a biomarker-first plan.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Merck — Checkpoint-franchise adjacency and combination-trial appetite. AstraZeneca — Oncology breadth plus interest in biomarker-defined populations. Roche / Genentech — Diagnostics plus oncology translational machinery.

Development Strategy to Increase PoS

First indication: Psychiatry/Mental Health

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Reframe as a localized orphan-retina or front-of-eye precision program Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Reframe as a localized orphan-retina or front-of-eye precision program

Best next experiment: Run the smallest independent study that validates: Switch from systemic exposure to intravitreal, topical, or depot delivery and use OCT/ERG/imaging biomarkers as early go/no-go endpoints.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.